MKI67 and neoplasm: Consistently, at cellular level, enzalutamide significantly inhibited tumor cell proliferation as measured by Ki-67 staining after 4 d into the treatment (Fig. S2, D and E) and induced apoptosis as measured by cleaved caspase 3 staining after 7 d into the treatment (Fig. S2, F and G) in the MycCaP-Bo model.